Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

Citius Oncology, Inc. is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc.